|Standard Report||Premium Report|
|Current State of the Industry|
|Market Size (industry trends)|
|Market Forecast (5-year projection)|
|Revenue per State|
|Salary & Compensation Statistics|
|Public Company Information|
|Key Private Companies|
|Instant Download - Available immediately upon purchase|
|Download both PDF and Excel
2020 U.S. Industry Statistics & Market Research - Pharmaceutical Preparation Manufacturing
Market Size & Industry Statistics
The total U.S. industry market size for Pharmaceutical Preparation Manufacturing:
Industry statistics cover all companies in the United States, both public and private, ranging in size from small businesses to market leaders.
In addition to revenue, the industry market analysis shows information on employees, companies, and average firm size.
Investors, banks, and business executives use growth rates and industry trends to understand the market outlook and opportunity.
|Statistics||2014 2015 2016 2017 2018 2019|
Order at top of page
|Average Revenue Per Firm|
|Average Employees Per Firm|
|Average Revenue Per Employee|
Market forecasts show the long term industry outlook and future growth trends. The following extended five-year / six-year demand forecast projects both short-term and long-term trends.
|Forecast / Industry Outlook||2020||2021||2022||2023||2024||2025|
|Market Forecast ($ millions)|
|Projected Industry Growth Rate (%)|
Product & Services BreakdownResearch products and services in the Pharmaceutical Preparation Manufacturing industry generating sales. Note that products are broken into categories with different levels of classification.
|Product Description||Sales ($ millions)||Percent of Total Sales|
Medicinal And Botanical Manufacturing
Synthetic Organic Medicinal Chemicals (All Uses), Medicinal And Botanical Drugs, Chemicals, And Products, In Bulk, Alkaloid Drug
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations, Acting On The Central Nervous System And The Sense Organs, For Human Use
Pharmaceutical Preparations, Acting On The Cardiovascular System, For Human Use
Pharmaceutical Preparations, Acting On The Respiratory System, For Human Use
Pharmaceutical Preparations, Acting On Skin, For Human Use
Pharmaceutical Preparations, Vitamin, Nutrient, And Hematinic Preparations, For Human Use
Pharmaceutical Preparations, Affecting Parasitic And Infective Diseases, For Human Use (Excluding Diagnostics)
Pharmaceutical Preparation Manufacturing, Not Categorized, Total
Biological Product (Except Diagnostic) Manufacturing
Other Biologics, Excluding Diagnostic, For Human Use
Toilet Preparation Manufacturing
Creams, Lotions And Oils, Excluding Shaving, Hair, And Deodorant
Total Miscellaneous Receipts
Resales - Sales Of Products Bought And Sold Without Further Manufacture, Processing, Or Assembly
Contract Work - Receipts For Work Done For Others On Their Materials
Miscellaneous Receipts, Including Receipts For Repair Work, Sales Of Scrap And Refuse.
U.S. Geographic Distribution: Revenue Statistics by StateMarket Size by State ($ millions) indicates how the industry's competition is distributed throughout the country. State-level information can identify areas with higher and lower industry market share than average.
Pharmaceutical Preparation Manufacturing Industry Price TrendsRise and fall in market prices are affectedd by supply, demand, and the cost of goods/services sold. Higher demand or COGS will put upward price pressure on prices. Higher competition among Pharmaceutical Preparation Manufacturing companies will put a downward pressure on prices. The chart shows how prices are changing within the industry, month-to-month over the last three years.
Income Statement (Average Financial Metrics)Financial metrics provide a snapshot view of a benchmark "average" company. Key business metrics show revenue and operating costs. The data collected covers both public and private companies.
|Industry Average||Percent of Sales|
Order at top of page
|Cost of Goods Sold|
|Pension, profit sharing plans, stock, annuity|
|Rent paid on business property|
|Domestic production activities deduction|
|Compensation of officers|
|Salaries and wages|
|Employee benefit programs|
|Taxes and Licenses|
|Other Operating Expenses|
|Total Operating Expenses|
|EBIT (Earnings Before Interest and Taxes)|
|Earnings Before Taxes|
Financial Ratio AnalysisFinancial ratio information can be used to benchmark how a Pharmaceutical Preparation Manufacturing company compares to its peers. Accounting statistics are calculated from the industry-average for income statements and balance sheets.
|Profitability & Valuation Ratios||Industry Average|
|Company valuation can be measured based on the firm's own performance, as well as in comparison against its industry competitors. These metrics show how the average company in the Pharmaceutical Preparation Manufacturing industry is performing.|
Gross Profit Margin, Operating Profit Margin, and Net Profit Margin. Show company earnings relative to revenues.
|Return on Equity (ROE)
Return on Equity (ROE) is net income as a percentage of shareholders' equity. Shareholders' Equity is defined as the company's total assets minus total liabilities. ROE shows how much profits a company generates with the money shareholders invested (or with retained earnings).
|Return on Assets (ROA)
Return on Assets (ROA) is net income relative to total assets. The market research on Pharmaceutical Preparation Manufacturing measures how efficiently the company leverages its assets to generate profit. ROA is calculated as Net Income divided by Total Assets.
|Liquidity Ratios||Industry Average|
|Bankers and suppliers use liquidity to determine creditworthiness and identify potential threats to a company's financial viability.|
Measures a firm's ability to pay its debts over the next 12 months.
|Quick Ratio (Acid Test)
Calculates liquid assets relative to liabilities, excluding inventories.
|Efficiency Ratios - Key Performance Indicators||Industry Average|
|Measure how quickly products and services sell, and effectively collections policies are implemented.|
|Receivables Turnover Ratio
If this number is low in your business when compared to the industry average in the research report, it may mean your payment terms are too lenient or that you are not doing a good enough job on collections.
|Average Collection Period
Based on the Receivables Turnover, this estimates the collection period in days. Calculated as 365 divided by the Receivables Turnover
A low turnover rate may point to overstocking, obsolescence, or deficiencies in the product line or marketing effort.
Generally, higher is better, since it indicates the business has less money tied up in fixed assets for each dollar of sales revenue.
Compensation & Salary Surveys for EmployeesCompensation statistics provides an accurate assessment of industry-specific jobs and national salary averages. This information can be used to identify which positions are most common, and high, low, and average annual wages.
|Title||Percent of Workforce||Bottom Quartile||Average (Median) Salary||Upper Quartile|
Order at top of page
|General and Operations Managers||2%|
|Business and Financial Operations Occupations||8%|
|Business Operations Specialists||7%|
|Architecture and Engineering Occupations||6%|
|Life, Physical, and Social Science Occupations||16%|
|Chemists and Materials Scientists||6%|
|Office and Administrative Support Occupations||8%|
|Other Production Occupations||26%|
|Packaging and Filling Machine Operators and Tenders||9%|
|Packaging and Filling Machine Operators and Tenders||9%|
Pharmaceutical Preparation Manufacturing Competitor Landscape & Key Companies [PREMIUM]The most influential companies in the Pharmaceutical Preparation Manufacturing industry and adjacent industries either have large market share or are developing new business models and methods that could disrupt the status quo. We look at leading and emerging companies in the Pharmaceutical Preparation Manufacturing industry and adjacent sectors:
Companies with the largest market share, focused in this industry
|Market leaders: |
Largest companies that have diversified operations in this and other industries
Innovative, Emerging, and Disruptive Companies that may influence the future direction of the industry.
Innovators and Disruptors in adjacent industries that may also affect the Pharmaceutical Preparation Manufacturing industry.
Our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. We believe that key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, price and reimbursement level. Many of our potential competitors, including many of the organizations named below, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining the FDA’s and other regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors’ drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our product candidates. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Further, the development of new treatment methods for the conditions we are targeting could render our drugs non-competitive or obsolete. COVID-19 Vaccine Development Projects The activity for developing vaccines for COVID-2019 is competitive and includes companies and academic institutions. GlaxoSmithKline (GSK) / Clover Biopharmaceuticals, Novavax, Altimmune, Vaxart, Generex Biotechnology, Vaxil Bio, iBio, Baylor College of Medicine / New York Blood Center, University of Queensland, University of Saskatchewan, University of Oxford / Advent Srl are working on protein-based vaccines. Smallpox vaccines and antivirals A number of companies are marketing or developing vaccines and treatments for smallpox, including Emergent BioSolutions, Bavarian Nordic, SIGA Technologies and Chimerix. Emergent BioSolutions markets ACAM2000, which is a replicating vaccinia vaccine for the prevention of smallpox. Bavarian Nordic received FDA approval and markets Jynneos® (or Modified Virus Ankara, strain BN or MVA-BN), which is a non-replicating vaccinia virus vaccine for the prevention of smallpox and monkeypox. SIGA received FDA approval and markets TPOXX® (tecovirimat), which is an antiviral for smallpox. 26 CNS Condition Therapeutics The market for therapies to treat FM, PTSD and other CNS conditions is well developed and populated with established drugs marketed by large and small pharmaceutical, biotechnology and generic drug companies. A number of companies are developing prescription medicines for FM, including Aptinyx (NYX-2925), Innovative Medical Concepts (celecoxib and famciclovir or IMC-1) and Axsome (eseboxetine or AXS-14). PTSD In PTSD GlaxoSmithKline (Paxil®) and Pfizer (Zoloft®) developed and market Paxil® and Zoloft®, respectively for PTSD that are approved by the FDA. Certain other companies and institutions are known to be developing prescription medications for PTSD, including Bionomics (BNC-201), Otsuka/Lundbeck (Rexulti® [brexpiprazole]), Uniformed Services University of the Health Sciences (riluzole), the Multidisciplinary Association of Psychedelic Studies (methylenedioxymethamphetamine [MDMA]) and Aptinyx (NYX-783). Brainsway Ltd., a medical device company, is currently recruiting patients for a pivotal Phase 3 trial using a deep transcranial magnetic stimulation device for treatment of PTSD. A number of other companies and institutions have or may be developing prescription medications for PTSD, including: Mt. Sinai Hospital and Medical School in New York City is developing ketamine which is in Phase 2 and targets the NMDA receptor, Azevan Pharmaceuticals is developing SRX246 which is in Phase 2 and targets the vasopressin V1A receptor, University of California, San Diego (UCSD) is developing losartan which is in Phase 2 and is an angiotensin receptor blocker (ARB), Massachusetts General Hospital (MGH), University of California, San Francisco (UCSF) are developing oxytocin which is in Phase 2 and targets the oxytocin receptor, Nobilis Therapeutics is developing NBTX-001, a noble gas, which is in Phase 2, EpiVario is developing inhibitors of Acetyl CoA synthetase, which is in Phase 1 and Seelos Therapeutics (recently merged with Apricus Biosciences) is developing an intranasal racemic ketamine to treat PTSD and major depressive disorder (MDD). Several companies have clinical candidates for which PTSD is being considered as a secondary indication. Agitation in Alzheimer’s Disease Additionally, a number of companies are developing prescription medicines for AAD, including Otsuka/Lundbeck (Rexulti® or brexpiprazole), Avanir/Otsuka (deudextromethorphan), Axsome (dextromethorphan/buproprion) and InterCellular (lumateperone). Lumateperone is in Phase 3 for treating behavioral disturbances associated with dementia and was recently approved as CAPLYTA® for the treatment of schizophrenia. Although a number of companies are marketing or developing prescription medicines for sleep disorders, including Merck Tonix Pharmaceuticals Holding
Government ContractsIn 2020, the federal government spent a total of $3,238,983,457 on Pharmaceutical Preparation Manufacturing. It has awarded 4823 contracts to 608 companies, with an average value of $5,327,275 per company.
|Most Recent Contracts||Date||Total Award Amount|
|UNITED THERAPEUTICS CORPORATION |
1040 Spring St
Silver Spring, MD
|Sep 26, 2020||$33,808|
|CSL BEHRING L.L.C. |
1020 1st Ave
King Of Prussia, PA
|Sep 25, 2020||$6,544|
|RLS USA INC. |
3350 N Ridge Ave
Arlington Heights, IL
|Sep 25, 2020||$656,250|
|BAUSCH HEALTH US, LLC |
400 Somerset Corporate Blvd
|Sep 25, 2020||$20,156|
|QUVA PHARMA, INC. |
1075 W Park One Dr Ste 100
Sugar Land, TX
|Sep 25, 2020||$86,243|
|MCKESSON CORPORATION |
6555 State Highway 161
|Sep 25, 2020||$24,047|